In this issue:
Vitamin D may boost ICI efficacy
Adjuvant nivolumab prolongs RFS vs ipilimumab
CheckMate 401: First-line ICI combo strategy for unresectable melanoma
Determinants of survival in metastatic uveal melanoma
Neoadjuvant-adjuvant immunotherapy a new paradigm for advanced disease
Treatment-free survival benefit to combination immunotherapy
CAP 03: Camrelizumab + apatinib + temozolomide for acral melanoma
Tebentafusp + ICI combos have anti-tumour activity in cutaneous melanoma
PBAC recommendations
PBS listings
TIL is prognostic in primary melanoma
Nivolumab + relatlimab active in disease progressing on anti–PD-(L)1 therapy
Novel predictive model improves identification of lymph node involvement
Race disparities in timely treatment in the US
COVID-19 resources
Conferences, workshops and CPD
Please login below to download this issue (PDF)